Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SB719125
- Development stage
- Phase 1
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
**SB719125** is an investigational recombinant vaccine developed by GSK for immunotherapy in HER2-overexpressing breast cancer. It consists of a recombinant dHER2 protein (a modified form of the HER2 antigen) combined with the AS15 adjuvant system, designed to elicit robust immune responses against HER2-positive tumor cells. The vaccine was evaluated in early-phase clinical trials for safety, immunogenicity, and preliminary efficacy in high-risk and metastatic breast cancer patients, showing completion of Phase 1 and 2 studies but no further advancement reported.
- Other names
- dHER2 + AS15 ASCIdHER2 ASCIdHER-2 ASCIdHER 2 ASCI
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on SB719125.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SB719125.